Dual effects of RAS blockade on blood pressure and podocyte function

[1]  B. Schermer,et al.  Podocin Organizes Ion Channel-Lipid Supercomplexes: Implications for Mechanosensation at the Slit Diaphragm , 2007, Nephron Experimental Nephrology.

[2]  G. Bakris,et al.  Microalbuminuria: What Is It? Why Is It Important? What Should Be Done About It? An Update , 2007, Journal of clinical hypertension.

[3]  M. Rastaldi,et al.  Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[4]  John McAnally,et al.  TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. , 2006, The Journal of clinical investigation.

[5]  M. Chalfie,et al.  Podocin and MEC-2 bind cholesterol to regulate the activity of associated ion channels , 2006, Proceedings of the National Academy of Sciences.

[6]  J. Soboloff,et al.  A common mechanism underlies stretch activation and receptor activation of TRPC6 channels , 2006, Proceedings of the National Academy of Sciences.

[7]  G. Zalba,et al.  Oxidative stress and atherosclerosis in early chronic kidney disease. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  S. Shankland,et al.  The renin-angiotensin system in glomerular podocytes: Mediator of glomerulosclerosis and link to hypertensive nephropathy , 2006, Current hypertension reports.

[9]  Jaakko Patrakka,et al.  Hereditary proteinuria syndromes and mechanisms of proteinuria. , 2006, The New England journal of medicine.

[10]  H. Pavenstädt,et al.  Functional expression of the renin-angiotensin system in human podocytes. , 2006, American journal of physiology. Renal physiology.

[11]  D. Clapham,et al.  TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function , 2005, Nature Genetics.

[12]  L. Smeeth,et al.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis , 2005, The Lancet.

[13]  M. Kinter,et al.  Proteomic analysis of TRPC5- and TRPC6-binding partners reveals interaction with the plasmalemmal Na+/K+-ATPase , 2005, Pflügers Archiv.

[14]  Jason A. Mitchell,et al.  Early recognition and treatment of hypertensive heart disease , 2005, Current opinion in cardiology.

[15]  Neil Chapman,et al.  Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. , 2005, Archives of internal medicine.

[16]  M. Pericak-Vance,et al.  A Mutation in the TRPC6 Cation Channel Causes Familial Focal Segmental Glomerulosclerosis , 2005, Science.

[17]  G. Wolf,et al.  From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. , 2005, Diabetes.

[18]  J. Egido,et al.  Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. , 2005, American journal of hypertension.

[19]  W. Kriz,et al.  Pathways to nephron loss starting from glomerular diseases-insights from animal models. , 2005, Kidney international.

[20]  W. Couser,et al.  Mechanical stretch induces podocyte hypertrophy in vitro. , 2005, Kidney international.

[21]  N. Gretz,et al.  J Am Soc Nephrol 15: 1475–1487, 2004 Angiotensin II Type 1 Receptor Overexpression in Podocytes Induces Glomerulosclerosis in Transgenic Rats , 2022 .

[22]  J. Duarte,et al.  Protective effects of the angiotensin II type 1 (AT1) receptor blockade in low-renin deoxycorticosterone acetate (DOCA)-treated spontaneously hypertensive rats. , 2004, Clinical science.

[23]  W. Kriz,et al.  Structure and function of podocytes: an update , 1995, Anatomy and Embryology.

[24]  W. Couser,et al.  Activation of a local tissue angiotensin system in podocytes by mechanical strain. , 2004, Kidney international.

[25]  David E. Clapham,et al.  TRP channels as cellular sensors , 2003, Nature.

[26]  K. Asanuma,et al.  The role of podocytes in glomerular pathobiology , 2003, Journal of Clinical and Experimental Nephrology.

[27]  M. Cerrito,et al.  Angiotensin-Converting Enzyme Inhibition Modulates High-Glucose-Induced Extracellular Matrix Changes in Mouse Glomerular Epithelial Cells , 2003, Nephron Experimental Nephrology.

[28]  Jackson T. Wright,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial , 2003 .

[29]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[30]  Matthias Kretzler,et al.  Cell biology of the glomerular podocyte. , 2003, Physiological reviews.

[31]  Marta Ruiz-Ortega,et al.  Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. , 2002, Kidney international. Supplement.

[32]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[33]  M. Ravera,et al.  Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers. , 2002, Journal of the American Society of Nephrology : JASN.

[34]  D. Kerjaschki.  Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. , 2001, The Journal of clinical investigation.

[35]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[36]  M. Farquhar,et al.  Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. , 2001, The Journal of clinical investigation.

[37]  M. Cooper,et al.  Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension , 2001, Diabetologia.

[38]  G. Remuzzi,et al.  Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. , 2001, Journal of the American Society of Nephrology : JASN.

[39]  D. Uttenweiler,et al.  Podocytes respond to mechanical stress in vitro. , 2001, Journal of the American Society of Nephrology : JASN.

[40]  A. Fogo.  Renal fibrosis and the renin-angiotensin system. , 2001, Advances in nephrology from the Necker Hospital.

[41]  M. Ushio-Fukai,et al.  Reactive oxygen species as mediators of angiotensin II signaling , 2000, Regulatory Peptides.

[42]  R. Schrier,et al.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.

[43]  A. Kshirsagar,et al.  Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[44]  S. Somlo,et al.  Getting a foothold in nephrotic syndrome , 2000, Nature Genetics.

[45]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases in renal development and disease. , 2000, Journal of the American Society of Nephrology : JASN.

[46]  G. Remuzzi,et al.  Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. , 2000, Journal of the American Society of Nephrology : JASN.

[47]  G. Navis,et al.  Chronic angiotensin II infusion but not bradykinin blockade abolishes the antiproteinuric response to angiotensin-converting enzyme inhibition in established adriamycin nephrosis. , 2000, Journal of the American Society of Nephrology : JASN.

[48]  V. Dzau,et al.  The renin-angiotensin-aldosterone system: a specific target for hypertension management. , 1999, American journal of hypertension.

[49]  R. Brandes,et al.  Role of xanthine oxidase in passive Heymann nephritis in rats. , 1999, Journal of the American Society of Nephrology : JASN.

[50]  K. Kurokawa.  Effects of candesartan on the proteinuria of chronic glomerulonephritis , 1999, Journal of Human Hypertension.

[51]  N. Gretz,et al.  From segmental glomerulosclerosis to total nephron degeneration and interstitial fibrosis: a histopathological study in rat models and human glomerulopathies. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  N. Gretz,et al.  Progression of glomerular diseases: is the podocyte the culprit? , 1998, Kidney international.

[53]  J. Gloy,et al.  Catecholamines modulate podocyte function. , 1998, Journal of the American Society of Nephrology : JASN.

[54]  G. Bakris,et al.  Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease. , 1997, Kidney international. Supplement.

[55]  H. Pavenstädt,et al.  Angiotensin II increases the cytosolic calcium activity in rat podocytes in culture. , 1997, Kidney international.

[56]  J. Gloy,et al.  Angiotensin II depolarizes podocytes in the intact glomerulus of the Rat. , 1997, The Journal of clinical investigation.

[57]  S. Rajagopalan,et al.  Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. , 1997, Circulation.

[58]  G. Mayer,et al.  Reactive oxygen species and glomerular injury. , 1996, Kidney & blood pressure research.

[59]  B. Kasiske,et al.  The angiotensin II receptor antagonist losartan reduces blood pressure but not renal injury in obese Zucker rats. , 1995, Journal of the American Society of Nephrology : JASN.

[60]  R W Alexander,et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.

[61]  J. Sadoshima,et al.  Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro , 1993, Cell.

[62]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[63]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[64]  E. Ritz,et al.  The effect of enalapril on glomerular growth and glomerular lesions after subtotal nephrectomy in the rat: a stereological analysis , 1993, Journal of hypertension.

[65]  D. Kerjaschki,et al.  Reactive oxygen species and neutrophil respiratory burst cytochrome b558 are produced by kidney glomerular cells in passive Heymann nephritis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[66]  J. Laragh,et al.  Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats. , 1992, Journal of hypertension.

[67]  R. Franke,et al.  Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytes of chicken, rat, and man. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[68]  L. Monnier,et al.  Influence of Indigestible Fibers on Glucose Tolerance , 1978, Diabetes Care.